Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

1.

The epidemiologic evidence underlying recommendations for use of pneumococcal polysaccharide vaccine among American Indian and Alaska Native populations.

Said MA, O'Brien KL, Nuorti JP, Singleton R, Whitney CG, Hennessy TW.

Vaccine. 2011 Jul 26;29(33):5355-62. doi: 10.1016/j.vaccine.2011.05.086. Epub 2011 Jun 12.

PMID:
21664217
[PubMed - indexed for MEDLINE]
2.
3.

Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).

Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices.

MMWR Morb Mortal Wkly Rep. 2010 Sep 3;59(34):1102-6.

PMID:
20814406
[PubMed - indexed for MEDLINE]
Free Article
4.

Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Advisory Committee on Immunization Practices.

MMWR Recomm Rep. 2000 Oct 6;49(RR-9):1-35.

PMID:
11055835
[PubMed - indexed for MEDLINE]
Free Article
5.

Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era.

Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, Lexau C, Damaske B, Stefonek K, Barnes B, Patterson J, Zell ER, Schuchat A, Whitney CG; Active Bacterial Core Surveillance (ABCs)/Emerging Infections Program Network.

JAMA. 2001 Apr 4;285(13):1729-35.

PMID:
11277827
[PubMed - indexed for MEDLINE]
7.

Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).

American Academy of Pediatrics Committee on Infectious Diseases.

Pediatrics. 2010 Jul;126(1):186-90. doi: 10.1542/peds.2010-1280. Epub 2010 May 24.

PMID:
20498180
[PubMed - indexed for MEDLINE]
Free Article
8.

Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.

Lacapa R, Bliss SJ, Larzelere-Hinton F, Eagle KJ, McGinty DJ, Parkinson AJ, Santosham M, Craig MJ, O'Brien KL.

Clin Infect Dis. 2008 Aug 15;47(4):476-84. doi: 10.1086/590001.

PMID:
18627249
[PubMed - indexed for MEDLINE]
Free Article
9.

Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2010 Mar 12;59(9):258-61.

PMID:
20224542
[PubMed - indexed for MEDLINE]
Free Article
10.

Invasive pneumococcal disease epidemiology and effectiveness of 23-valent pneumococcal polysaccharide vaccine in Alaska native adults.

Singleton RJ, Butler JC, Bulkow LR, Hurlburt D, O'Brien KL, Doan W, Parkinson AJ, Hennessy TW.

Vaccine. 2007 Mar 8;25(12):2288-95. Epub 2006 Dec 11.

PMID:
17254673
[PubMed - indexed for MEDLINE]
11.

Invasive pneumococcal disease a decade after pneumococcal conjugate vaccine use in an American Indian population at high risk for disease.

Weatherholtz R, Millar EV, Moulton LH, Reid R, Rudolph K, Santosham M, O'Brien KL.

Clin Infect Dis. 2010 May 1;50(9):1238-46. doi: 10.1086/651680.

PMID:
20367225
[PubMed - indexed for MEDLINE]
Free Article
12.
13.

Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage.

Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, Butler JC, Rudolph K, Parkinson A.

JAMA. 2007 Apr 25;297(16):1784-92.

PMID:
17456820
[PubMed - indexed for MEDLINE]
14.

Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2010 Mar 12;59(9):253-7.

PMID:
20224541
[PubMed - indexed for MEDLINE]
Free Article
15.

The epidemiology of invasive pneumococcal disease in Alaska, 1986-1990--ethnic differences and opportunities for prevention.

Davidson M, Parkinson AJ, Bulkow LR, Fitzgerald MA, Peters HV, Parks DJ.

J Infect Dis. 1994 Aug;170(2):368-76.

PMID:
8035023
[PubMed - indexed for MEDLINE]
17.

Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.

Cho BH, Stoecker C, Link-Gelles R, Moore MR.

Vaccine. 2013 Dec 5;31(50):6011-21. doi: 10.1016/j.vaccine.2013.10.024. Epub 2013 Oct 19.

PMID:
24148572
[PubMed - indexed for MEDLINE]
18.

Preventability of invasive pneumococcal disease and assessment of current polysaccharide vaccine recommendations for adults: United States, 2001-2003.

Greene CM, Kyaw MH, Ray SM, Schaffner W, Lynfield R, Barrett NL, Long C, Gershman K, Pilishvili T, Roberson A, Zell ER, Whitney CG, Bennett NM; Active Bacterial Core Surveillance Program of the Emerging Infections Program Network.

Clin Infect Dis. 2006 Jul 15;43(2):141-50. Epub 2006 Jun 9.

PMID:
16779739
[PubMed - indexed for MEDLINE]
Free Article
19.

Uptake of pneumococcal polysaccharide vaccination among working-age adults with underlying medical conditions, United States, 2009.

Lu PJ, Nuorti JP.

Am J Epidemiol. 2012 Apr 15;175(8):827-37. doi: 10.1093/aje/kwr376. Epub 2012 Mar 8.

PMID:
22403807
[PubMed - indexed for MEDLINE]
Free Article
20.

Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2012 Jun 1;61(21):394-5.

PMID:
22647745
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk